67000-35-5

Usage

Uses

Used in Organic Synthesis:
1-(2-bromoethyl)-3,5-dimethyl-1H-pyrazole is utilized as a key intermediate in the synthesis of a wide range of compounds, thanks to its unique chemical properties and reactivity. Its ability to form diverse chemical bonds makes it a valuable component in creating complex molecular structures.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(2-bromoethyl)-3,5-dimethyl-1H-pyrazole is employed as a precursor for the development of new drugs. Its structural features allow for the creation of bioactive molecules with potential therapeutic applications, making it an essential tool in drug discovery and design.
Used in Agrochemicals Production:
1-(2-bromoethyl)-3,5-dimethyl-1H-pyrazole also finds application in the agrochemical sector, where it serves as a starting material for the synthesis of various agrochemicals. Its role in this industry highlights the compound's versatility and its potential to contribute to different areas of science and technology.

Upstream product

• 67-51-6 3,5-dimethyl-1H-pyrazole 
• 106-93-4 ethylene dibromide 

Downstream Products

• 1384873-54-4 N-[2-(4-bromophenyl)ethyl]-N-{2-[(O)-tert-butylcarboxamido]ethyl}-N-[2-(3,5-dimethylpyrazol-2-yl)ethyl]amine 
• 1259313-17-1 benzyl 4-((2-(3,5-dimethylpyrazol-1-yl)ethyl)(2-ethoxy-2-oxoethyl)amino)butanoate 
• 1259313-36-4 ethyl 2-((4-(4-(2-(diethylamino)ethylcarbamoyl)phenylamino)-4-oxobutyl)(2-(3,5-dimethypyrazol-1-yl)ethyl)amino)acetic acid 
• 1259313-20-6 ethyl 2-((4-(4-(2-(diethylamino)ethylcarbamoyl)phenylamino)-4-oxobutyl)(2-(3,5-dimethylpyrazol-1-yl)ethyl)amino)acetate 
• 62821-88-9 2-(3,5-dimethyl-1H-pyrazol-1-yl)ethan-1-amine 
• 927883-71-4 (4-EtO₂CCH₂-3,5-Me₂pyrazolyl)(CH₂)2NH-Gly-CH₂S(trityl) 
• 186667-02-7 methyl N-2-(3,5-dimethylpyrazol-1-yl)ethyliminodiacetate 
• 122823-19-2 N-{1-[2-(3,5-Dimethyl-pyrazol-1-yl)-ethyl]-4-phenyl-piperidin-4-yl}-N-(2-fluoro-phenyl)-propionamide 

Relevant academic research and scientific papers

2-(BICYCLO-HETEROARYL)-ISONICOTINIC DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to compounds of Formula (I) as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

Novel estradiol based metal complexes of Tc-99m

Aiming to contribute to the design of technetium imaging agents for estrogen receptor (ER) positive breast tumors, we have synthesized and evaluated the novel organometallic estradiol complexes (fac-[M(CO)3(κ 3-10)]+ and f

Synthesis, characterization and structures of 2-(3,5-dimethylpyrazol-1-yl) ethylseleno derivatives and their probable glutathione peroxidase (GPx) like activity

A series of 2-(3,5-dimethylpyrazol-1-yl)ethylseleno derivatives has been synthesized. The glutathione peroxidase like catalytic activity of these compounds has been studied in a model system, in which reduction of hydrogen peroxide with dithiothreitol (DTTred), in the presence of an organoselenium compound was investigated by 1H NMR spectroscopy. All these compounds exhibit GPx like catalytic activities and the catalytic reaction proceeds through a selenoxide intermediate, identified by 77Se{ 1H} NMR spectroscopy.

N-2-(Azol-1(2)-yl)ethyliminodiacetic acids: A novel series of Gd(III) chelators as T2 relaxation agents for magnetic resonance imaging

The synthesis, physicochemical properties, and toxicological implications of a novel series of N-2-(azol-1(2)-yl)ethyliminodiacetic acids, useful as contrast agents for magnetic resonance imaging are reported. Compounds were prepared by alkylation of methyl iminodiacetate with N-2-bromoethylazoles and subsequent hydrolysis. Stability constants of the corresponding Gd(III) complexes and T1 and T2 relaxivities were determined and interpreted in terms of optimized geometries obtained by semiempirical PM3 calculations. Compounds show increased T2 relaxivity and decreased toxicity in vitro as compared to EDTA-Gd(III) complexes. Copyright (C) 1999 Elsevier Science Ltd.

Synthesis, structure (NMR and mass spectrometry) and conformational analysis of heterocyclic analogues of dibenzocycloocta-1,5-diene: 5,6,12,13-tetrahydrobispyrazotetraazocinediium dihalides

Several 5,6,12,13-tetrahydrobispyrazotetraazocinediium dihalides 4a-d and 8 are prepared from pyrazole, 3,5-dimethylpyrazole, 4-(1-adamantyl)pyrazole and camphopyrazole by stepwise alkylation with 1,2-dibromoethane or 1,2-dichloroethane.Their structural characterization has been achieved by NMR and mass spectrometry.Dynamic NMR spectroscopy allowed the measurement of the barrier for the chair-chair interconversion in the case of the parent compound 4a and the 1,3,8,10-tetramethyl derivative 4b.These barriers as well as the preferred chair conformation are rationalized through semi-empirical and molecular mechanics calculations with regard to dibenzocycloocta-1,5-diene.The study of doubly charged bispyrazolium salts allows demonstration of their reduction by addition of a hydride ion ++ + H- -> (C + H)+> during FABMS experiments.